Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01451502 · ClinicalTrials.gov registry record · NA
Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
A NA study of Lymphatic Diseases and Hematopoietic Malignancy, sponsored by Masonic Cancer Center, University of Minnesota.
- Recruiting
- Registry status
- NA
- Development phase
- 250
- Enrollment target
- 1
- Study location
NCT01451502: Recruiting NA study of Lymphatic Diseases and Hematopoietic Malignancy, sponsored by Masonic Cancer Center, University of Minnesota.
NCT01451502 is a NA study of Lymphatic Diseases and Hematopoietic Malignancy that is actively recruiting participants, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 250 participants, above the 222-participant average among 6 other Lymphatic Diseases trials with a reported enrollment target (13% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01451502, a NA study of Lymphatic Diseases and Hematopoietic Malignancy, is actively recruiting participants, sponsored by Masonic Cancer Center, University of Minnesota.
- RECRUITING
- Registry status
- NA
- Development phase
- 250 participants
- Enrollment target
- 1
- Study location
Study Summary
For the next 5-10 years or possibly longer, a high proportion of the Cord Blood Banks (CBB) inventory worldwide will be composed of unlicensed umbilical cord blood (UCB) units. While Food and Drug Administration (FDA)-licensed units will be prioritized, it will always be possible that an unlicensed unit will have known attributes, making it a better source of cells for the given indication. Because of the wide variety of current and potential indications as a source of cells for hematopoietic reconstitution or other form of cellular therapy, it is critical that the investigators have access to unlicensed UCB units.
Primary Outcome
Documentation of events for the purpose of this study will only be for those events at least possibly related to the unlicensed UCB. Monitoring for acute infusional toxicities will end 24 hours after the umbilical cord blood (UCB) infusion.
Conditions Studied
Interventions
- BIOLOGICAL Umbilical Cord Blood (UCB)
Study Locations (1)
Minnesota
- Masonic Cancer Center, University of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2011-10-20 |
| Est. Completion | 2026-12 |
| Phase | NA |
What NCT01451502 shows while recruiting
NCT01451502 is an interventional study that assigns participants to a tested intervention. The registered 250 participants enrollment target is mid-sized for trials with a published cap, above the 222-participant average among 6 other Lymphatic Diseases trials with a reported enrollment target (13% higher).
The record links to 2 conditions, with Lymphatic Diseases appearing as the primary indexed condition, and to 1 intervention - of which Umbilical Cord Blood (UCB) is the first listed.
NCT01451502 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT01451502 about?
NCT01451502 is a clinical study titled "Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units". For the next 5-10 years or possibly longer, a high proportion of the Cord Blood Banks (CBB) inventory worldwide will be composed of unlicensed umbilical cord blood (UCB) units. While Food and Drug Administration (FDA)-licensed units will be prioritized, it will always be possible that an unlicensed ...
What is the current status of trial NCT01451502?
This trial is currently recruiting. It is a NA study. The enrollment target is 250 participants. The study started on 2011-10-20. Estimated completion is 2026-12.
What conditions does trial NCT01451502 study?
This clinical trial studies the following conditions: Lymphatic Diseases, Hematopoietic Malignancy.
What interventions are being tested in trial NCT01451502?
The interventions under investigation include: Umbilical Cord Blood (UCB) (BIOLOGICAL).
Who is sponsoring clinical trial NCT01451502?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01451502 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphatic Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Prospective Natural History Study of Lymphatic Anomalies
RECRUITING
-
Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma
ACTIVE NOT RECRUITING · Phase 1
-
BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL
ACTIVE NOT RECRUITING · Phase 1
-
Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL
ACTIVE NOT RECRUITING · Phase 1
-
Administration of T Lymphocytes for Prevention of Relapse of Lymphomas
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00483249 · 250 participants · NA
Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm
- NCT00777712 · 250 participants
Mechanisms Underlying Impaired Diabetic Wound Healing
- NCT01771718 · 250 participants
Pilot Study on In-vivo Non-invasive Skin Imaging Using Multiphoton Microscopy
- NCT02021604 · 250 participants · Phase 1
Fluorodopa F 18 in Congenital Hyperinsulinism and Insulinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI